Navigation Links
Napo Obtains Special Protocol Assessment Agreement From FDA for Crofelemer

Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners , today announced that under the Special Protocol Assessment (SPA) process it has obtained agreement with the United States Food and Drug Administration (FDA) for the design of its pivotal study protocol for crofelemer for the treatment of chronic diarrhea in people with HIV/AIDS (CRO-HIV).

The study, also referred to as the ADVENT trial, will be carried out under an FDA Fast Track designation. On Jan. 16, 2007, Napo met with the FDA under the Special Protocol Assessment Process on this adaptive design of its ADVENT trial. On March 14, 2007, Napo announced it had received approval from the principal independent review board (IRB) overseeing the ADVENT trial.

The ADVENT trial -- (Anti-Diarrhea therapy in HIV disease-Emerging treatmeNT concepts) is a randomized, double-blind, parallel-group, placebo- controlled, two-stage, adaptive design study to assess the efficacy and safety of crofelemer at 125mg, 250 mg and 500 mg oral doses twice daily (p.o.b.i.d) for the treatment of HIV-Associated Diarrhea.

The 'adaptive design' of the ADVENT trial -- Adaptive trial design has been advocated by the FDA to improve efficiency of clinical trials. The ADVENT trial will be executed in two stages. Stage I represents a dose selection stage and Stage II, a dose assessment stage. Four dose groups (placebo, 125 mg, 250 mg, and 500 mg) will be assessed in Stage I. When 50 subjects per group complete the initial efficacy dosing period (28 days), an interim analysis will be conducted to select an optimal single dose of crofelemer for Stage II. Stage II will continue until an additional 75 subjects are randomized both to this dose of crofelemer and the placebo, providing for 125 patients on placebo and 125 patients the selected crofelemer dose. The primary study analysis is planned after all subjects complete the 28-day efficacy period. A full study analysis and final study report will be prepared at that time that will form the basis of a subsequent New Drug Application (NDA) filing to FDA. Subjects who complete the efficacy part of the study will be allowed to continue into an open-label, five-month extension. The purpose of the extension is to provide additional safety and tolerability information about crofelemer in longer tem use.

Commenting on this announcement, Lisa Conte, Chief Executive Officer of Napo Pharmaceuticals, said: "The SPA agreement is an important milestone for Napo, allowing us to address and mitigate regulatory uncertainty prior to the completion of our final Phase 3 trial in support of the Company's first NDA filing, targeted for early 2008."

Dr. Scott Harris, Vice President, Clinical Affairs, and Chief Medical Officer, said: "Napo has taken every effort to design and execute a Phase 3 program with the highest possible probability of success, incorporating experience from approximately 1,500 patients studied in clinical trials involving crofelemer. Already, 55 patients have enrolled in a previously conducted Feasibility Study of CRO-HIV. We expect these patients to be immediately eligible for enrolment for the ADVENT study."


'"/>




Related medicine news :

1. Special proteins to fight TB identified
2. Special proteins to fight TB identified
3. Specialist care convalesces intensive care survival
4. Specialist surgeon not imperative in melanoma
5. Treating Dental Problems Of Abused Children Need Special Care
6. Specialized Clinics For Manipurs AIDS Patients
7. Credentials Of Specialists Need To Be Checked
8. All Specialty Care Treatments Will Be Offered At Belle Vue.
9. Details of Cosmetic Surgery in a Special Website.
10. Omega-3 May Help Special Children
11. Inhospitable Response Curtail Growth Of Specialty Hospitals: United States
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... solutions for contaminated soil, dredged material, and hazardous and non-hazardous materials announced today ... Allentown, Pennsylvania. This acquisition will add four additional processing facilities and a ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... will spark a conversation on the current obstacles facing infection prevention and offer ... preventable deaths caused by these infections. , The print component of “Fighting ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software ... announce the opening of a Greenville, South Carolina location. The lab has ... in Greenville. , “We’ve been working with South Carolina clients for years from our ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, ... Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare would ... estimates a reduction in employer-based coverage due to the GOP reform, which is not ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to gain popularity. ... cannabis market will reach a value of USD 55.8 billion by 2025. ... new growing industry. By the end of 2016, 28 states have now ... More conservative states like Arkansas and ...
(Date:3/24/2017)... Today Stock-Callers.com have issued research reports on four ... NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: EW), ... companies are part of the Healthcare sector, which gave back ... , 2017, with the NYSE Health Care Index declining 0.2% ... the S&P 500 were down about 0.4% as a group. ...
(Date:3/24/2017)... 2017  Mirabilis Medical, a Seattle ... non-invasive surgery, announced today CE Mark authorization for ... uterine fibroids throughout the European Union.  The company ... the US Food and Drug Administration to begin ... the United States.  The Mirabilis System combines high-speed ...
Breaking Medicine Technology: